Josca M Schoonejans1,2, Heather L Blackmore3, Thomas J Ashmore3, Lucas C Pantaleão3, Luciana Pellegrini Pisani3,4, Laura Dearden3, John A Tadross3,5, Catherine E Aiken3,6, Denise S Fernandez-Twinn3, Susan E Ozanne7. 1. Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK. jm.schoonejans@gmail.com. 2. Department of Women and Children's Health, King's College London, London, UK. jm.schoonejans@gmail.com. 3. Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK. 4. Department of Bioscience, Laboratory of Nutrition and Endocrine Physiology, Federal University of São Paulo, Santos, Brazil. 5. Department of Pathology, University of Cambridge, Cambridge, UK. 6. Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, UK. 7. Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and MRC Metabolic Diseases Unit, University of Cambridge, Cambridge, UK. seo10@cam.ac.uk.
Abstract
AIMS/HYPOTHESIS: Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models. Using a mouse model, this study investigated the effects of maternal metformin intervention during obese glucose-intolerant pregnancy on adiposity, hepatic steatosis and markers of metabolic health of male and female offspring up to the age of 12 months. METHODS: C57BL/6J female mice were weaned onto either a control diet (Con) or, to induce pre-conception obesity, an obesogenic diet (Ob). The respective diets were maintained throughout pregnancy and lactation. These obese dams were then randomised to the untreated group or to receive 300 mg/kg oral metformin hydrochloride treatment (Ob-Met) daily during pregnancy. In male and female offspring, body weights and body composition were measured from 1 month until 12 months of age, when serum and tissues were collected for investigation of adipocyte cellularity (histology), adipose tissue inflammation (histology and quantitative RT-PCR), and hepatic steatosis and fibrosis (histochemistry and modified Folch assay). RESULTS: At 12 months of age, male Ob and Ob-Met offspring showed increased adiposity, adipocyte hypertrophy, elevated expression of proinflammatory genes, hyperleptinaemia and hepatic lipid accumulation compared with Con offspring. Male Ob-Met offspring failed to show hyperplasia between 8 weeks and 12 months, indicative of restricted adipose tissue expansion, resulting in increased immune cell infiltration and ectopic lipid deposition. Female Ob offspring were relatively protected from these phenotypes but Ob-Met female offspring showed increased adiposity, adipose tissue inflammation, hepatic lipid accumulation, hyperleptinaemia and hyperinsulinaemia compared with Con female offspring. CONCLUSIONS/ INTERPRETATION: Maternal metformin treatment of obese dams increased offspring metabolic risk factors in a sex- and age-dependent manner. These observations highlight the importance of following up offspring of both sexes beyond early adulthood after interventions during pregnancy. Our findings illustrate the complexity of balancing short-term benefits to mother and child vs any potential long-term metabolic effects on the offspring when prescribing therapeutic agents that cross the placenta.
AIMS/HYPOTHESIS: Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models. Using a mouse model, this study investigated the effects of maternal metformin intervention during obese glucose-intolerant pregnancy on adiposity, hepatic steatosis and markers of metabolic health of male and female offspring up to the age of 12 months. METHODS: C57BL/6J female mice were weaned onto either a control diet (Con) or, to induce pre-conception obesity, an obesogenic diet (Ob). The respective diets were maintained throughout pregnancy and lactation. These obese dams were then randomised to the untreated group or to receive 300 mg/kg oral metformin hydrochloride treatment (Ob-Met) daily during pregnancy. In male and female offspring, body weights and body composition were measured from 1 month until 12 months of age, when serum and tissues were collected for investigation of adipocyte cellularity (histology), adipose tissue inflammation (histology and quantitative RT-PCR), and hepatic steatosis and fibrosis (histochemistry and modified Folch assay). RESULTS: At 12 months of age, male Ob and Ob-Met offspring showed increased adiposity, adipocyte hypertrophy, elevated expression of proinflammatory genes, hyperleptinaemia and hepatic lipid accumulation compared with Con offspring. Male Ob-Met offspring failed to show hyperplasia between 8 weeks and 12 months, indicative of restricted adipose tissue expansion, resulting in increased immune cell infiltration and ectopic lipid deposition. Female Ob offspring were relatively protected from these phenotypes but Ob-Met female offspring showed increased adiposity, adipose tissue inflammation, hepatic lipid accumulation, hyperleptinaemia and hyperinsulinaemia compared with Con female offspring. CONCLUSIONS/ INTERPRETATION: Maternal metformin treatment of obese dams increased offspring metabolic risk factors in a sex- and age-dependent manner. These observations highlight the importance of following up offspring of both sexes beyond early adulthood after interventions during pregnancy. Our findings illustrate the complexity of balancing short-term benefits to mother and child vs any potential long-term metabolic effects on the offspring when prescribing therapeutic agents that cross the placenta.
Authors: H David McIntyre; Patrick Catalano; Cuilin Zhang; Gernot Desoye; Elisabeth R Mathiesen; Peter Damm Journal: Nat Rev Dis Primers Date: 2019-07-11 Impact factor: 52.329
Authors: Denice S Feig; Lois E Donovan; Bernard Zinman; J Johanna Sanchez; Elizabeth Asztalos; Edmond A Ryan; I George Fantus; Eileen Hutton; Anthony B Armson; Lorraine L Lipscombe; David Simmons; Jon F R Barrett; Paul J Karanicolas; Siobhan Tobin; H David McIntyre; Simon Yu Tian; George Tomlinson; Kellie E Murphy Journal: Lancet Diabetes Endocrinol Date: 2020-10 Impact factor: 32.069
Authors: Sara Eyal; Thomas R Easterling; Darcy Carr; Jason G Umans; Menachem Miodovnik; Gary D V Hankins; Shannon M Clark; Linda Risler; Joanne Wang; Edward J Kelly; Danny D Shen; Mary F Hebert Journal: Drug Metab Dispos Date: 2010-01-29 Impact factor: 3.922
Authors: N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda Journal: Diabetes Res Clin Pract Date: 2018-02-26 Impact factor: 5.602
Authors: Janet A Rowan; Elaine C Rush; Lindsay D Plank; Jun Lu; Victor Obolonkin; Suzette Coat; William M Hague Journal: BMJ Open Diabetes Res Care Date: 2018-04-13
Authors: Antonia Hufnagel; Denise S Fernandez-Twinn; Heather L Blackmore; Thomas J Ashmore; Robert A Heaton; Benjamin Jenkins; Albert Koulman; Iain P Hargreaves; Catherine E Aiken; Susan E Ozanne Journal: J Physiol Date: 2021-09-29 Impact factor: 6.228
Authors: Carolyn E Cesta; Jacqueline M Cohen; Laura Pazzagli; Brian T Bateman; Gabriella Bröms; Kristjana Einarsdóttir; Kari Furu; Alys Havard; Anna Heino; Sonia Hernandez-Diaz; Krista F Huybrechts; Øystein Karlstad; Helle Kieler; Jiong Li; Maarit K Leinonen; Hanne L Gulseth; Duong Tran; Yongfu Yu; Helga Zoega; Ingvild Odsbu Journal: BMJ Open Diabetes Res Care Date: 2019-11-02
Authors: Josca M Schoonejans; Heather L Blackmore; Thomas J Ashmore; Catherine E Aiken; Denise S Fernandez-Twinn; Susan E Ozanne Journal: Int J Mol Sci Date: 2021-07-28 Impact factor: 5.923